IN Silico Approach of Some Selected Honey Constituents as SARS-CoV-2 Main Protease (COVID-19) Inhibitors
Objectives: The emergence and spread of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), led researchers around the world to study the crystal structure of the main protease (Mpro), 3-chymotrypsin-like cysteine protease, which is an essential enzyme for processing polyproteins. Inhibition of this key activity in the life cycle of the virus is a target in the scientific search for a drug to overcome this disease. Honeybee products have demonstrated antiviral and other beneficial properties that could prove useful in this effort.
Methods: A molecular modeling approach was used to evaluate the activity of 6 active honeybee product compounds for the ability to inhibit the SARS-CoV-2 Mpro using Schrödinger Maestro v10.1 software (Schrödinger LLC, New York, NY, USA).
Results: All 6 of the ligands demonstrated good binding affinity with the receptor in different ways. Four compounds had strong binding affinity with a good glide score and may inhibit the SARS-CoV-2 Mpro and replication of the virus.
Conclusion: Honeybee product constituents may provide an effective ligand for SARS-CoV-2 Mpro inhibition and may be valuable in the search for COVID-19 therapeutic drugs.
1.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9.
3. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R.Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763–7.
4. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014;281:4085–96.
5. Gorbalenya AE, Baker SC, Baric RS, Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARSCoV-2. Nat Microbiol 2020;5:536–44.
6. Macchiagodena M, Pagliai M, Procacci P. Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling. Chem Phys Lett 2020;750:137489.
7. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of iMproved α-ketoamide inhibitors. Science 2020;368:409–12.
8. Liu C, Cai D, Zhang L, Tang W, Yan R, Guo H, et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res 2016;134:97–107.
9. Więckiewicz W, Miernik M, Więckiewicz M, Morawiec T. Does propolis help to maintain oral health? Evid Based Complement Alternat Med 2013;2013:351062.
10. Yusuf N, Irby C, Katiyar SK, Elmets CA. Photoprotective effects of green tea polyphenols. Photodermatol Photoimmunol Photomed 2007;23:48–56.
11. Tolba MF, Azab SS, Khalifa AE, Abdel-Rahman SZ, Abdel-Naim AB. Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: a review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects. IUBMB Life 2013;65:699–709.
12. Banskota AH, Tezuka Y, Kadota S. Recent progress in pharmacological research of propolis. Phytother Res 2001;15:561–71.
13. Burdock GA. Review of the biological properties and toxicity of bee propolis (propolis). Food Chem Toxicol 1998;36:347–63
14. Park YK, Alencar SM, Aguiar CL. Botanical origin and chemical composition of Brazilian propolis. J Agric Food Chem 2002;50:2502–6.
15. Sforcin JM, Bankova V. Propolis: is there a potential for the development of new drugs? J Ethnopharmacol 2011;133:253– 60.
16. Patel S. Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents. J Diet Suppl 2016;13:245–68.
17. Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy. (I). Origin, properties, usage and literature review. Contact Dermatitis 1987;17:163–70.
18. Patel S, Cichello S. Manuka honey: An emerging natural food with medicinal use. Nat Prod Bioprospect 2013;3:121–8.
19. Chan CW, Deadman BJ, Manley-Harris M, Wilkins AL, Alber DG, Harry E. Analysis of the flavonoid component of bioactive New Zealand mānuka (Leptospermum scoparium) honey and the isolation, characterisation and synthesis of an unusual pyrrole. Food Chem 2013;141:1772–81.
20. Oelschlaegel S, Gruner M, Wang PN, Boettcher A, KoellingSpeer I, Speer K. Classification and characterization of manuka honeys based on phenolic compounds and methylglyoxal. J Agric Food Chem 2012;60:7229–37.
21. Mandal MD, Mandal S. Honey: its medicinal property and antibacterial activity. Asian Pac J Trop Biomed 2011;1:154–60.
22. Sell SA, Wolfe PS, Spence AJ, Rodriguez IA, McCool JM, Petrella RL, et al. A preliminary study on the potential of manuka honey and platelet-rich plasma in wound healing. Int J Biomater 2012;2012:313781.
23. Tomblin V, Ferguson LR, Han DY, Murray P, Schlothauer R. Potential pathway of anti-inflammatory effect by New Zealand honeys. Int J Gen Med 2014;7:149–58.
24. Tonks AJ, Dudley E, Porter NG, Parton J, Brazier J, Smith EL, et al. A 5.8-kDa component of manuka honey stimulates immune cells via TLR4. J Leukoc Biol 2007;82:1147–55.
25. Alzahrani HA, Alsabehi R, Boukraâ L, Abdellah F, Bellik Y, Bakhotmah BA. Antibacterial and antioxidant potency of floral honeys from different botanical and geographical origins. Molecules 2012;17:10540–9.
26. Ishida Y, Gao R, Shah N, Bhargava P, Furune T, Kaul SC, et al. Anticancer Activity in Honeybee Propolis: Functional Insights to the Role of Caffeic Acid Phenethyl Ester and Its Complex With γ-Cyclodextrin. Integr Cancer Ther 2018;17:867–73.